QV Bioelectronics USA cooperation feasibility study

胶质母细胞瘤是最常见和最具侵袭性的成人原发脑癌。全球发病率为3-5/100,000人，而且还在上升，每年约有3000例英国确诊病例。目前还没有治愈的方法，患者的平均预期寿命只有14个月。电场疗法是肿瘤切除后应用的一种新的癌症治疗形式，它直接干扰细胞分裂，减缓肿瘤复发，延长生命。然而，NICE不建议将单一上市的胶质母细胞瘤设备用于NHS，因为患者的生活质量较差，成本效益较低。QV BioElectronics(QVB)正在开发GRACE，这是一种以集中和连续的方式提供电场治疗的新型植入物，可能会使胶质母细胞瘤患者的预期寿命翻一番，从而潜在地改善患者的预后，同时克服现有解决方案相关的生活质量问题。QVB正在寻求接触美国的合作伙伴，这些合作伙伴拥有专业知识、技术和资金，可以将Grace设备推向市场。QVB的设备仍处于临床前开发阶段，几年内不会准备好开给患者。QVB的技术未来将扩展到其他类型的脑瘤，创造一个总价值超过50亿GB/年的全球市场机会，同时为NHS患者提供一种新的治疗方法。这将为英国创造就业机会，并有助于巩固英国作为不断增长的生物电子领域全球领导者的地位。

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average.Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the single marketed device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) are developing GRACE, a novel implant that delivers electric field therapy in a focal and continuous manner, potentially doubling glioblastoma patient life expectancy, leading to potential improved patient outcomes whilst overcoming quality-of-life issues associated with existing solutions. QVB is seeking to access partners in the US who have specialist knowledge, technologies and capital available to bring the GRACE device to market. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, creating a combined global market opportunity worth over £5Bn/year, whilst providing a new treatment for NHS patients. This will generate UK jobs and help to cement the UK's position as global leaders in the growing field of bioelectronics.